Cadila gets USFDA nod for generic drug to treat Parkinson
New Delhi: Cadila Healthcare said it has received approval from the US health regulator to market Pramipexole Dihydrochloride extended-release tablets, used for treating Parkinson's disease, in the American market.
The company's subsidiary, Zydus Pharmaceuticals (USA) Inc, has received the final approval from the USFDA to market Pramipexole Dihydrochloride extended-release tablets in strengths of 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg, Cadila Healthcare said in a statement.
The drug is indicated to treat signs and symptoms of Parkinson's disease (PD).
The Ahmedabad-based firm also received final approval from the USFDA to market Nitrofurantoin Capsules USP, used for treating acute uncomplicated urinary tract infections, in the US market.
Both the drugs will be manufactured at Zydus group's formulations manufacturing facility at Moraiya, Ahmedabad.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd